• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 639-653 of 973 results

1111 Exhibit: Exhibit 1111 Madsbad

Document IPR2023-00724, No. 1111 Exhibit - Exhibit 1111 Madsbad (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

2422 Exhibit: EX2422 Jentadueto® Prescribing Information rev Aug 2017

Document IPR2023-00724, No. 2422 Exhibit - EX2422 Jentadueto® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2359 Exhibit: EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Di...

Document IPR2023-00724, No. 2359 Exhibit - EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Diabetes Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medica...

cite Cite Document
Analyze

2453 Exhibit: EX2453 US Food Drug Administration, DrugsFDA, Synjardy

Document IPR2023-00724, No. 2453 Exhibit - EX2453 US Food Drug Administration, DrugsFDA, Synjardy (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2479 Exhibit: EX2479 Nordrum, A, 11 Blockbuster Drugs to Watch in 2015, Intl Bus...

Document IPR2023-00724, No. 2479 Exhibit - EX2479 Nordrum, A, 11 Blockbuster Drugs to Watch in 2015, Intl Bus Times, httpwwwibtimescom11 blockbuster drugs watch 2015 1857100 Mar 24, 2015 (P....

cite Cite Document
Analyze

2496 Exhibit: EX2496 Novo Nordisk, Financial report for the period 1 January 2018...

Document IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2545 Exhibit: EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 C...

Document IPR2023-00724, No. 2545 Exhibit - EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 CFR 4222 and 42122b, Dr Reddy’s Laboratories Inc v Novo Nordisk AS, IPR2024 00009, P...

cite Cite Document
Analyze

2651 Exhibit: EX2651 Excerpt of Reply Expert Report of Dr Paul Dalby Regarding In...

Document IPR2023-00724, No. 2651 Exhibit - EX2651 Excerpt of Reply Expert Report of Dr Paul Dalby Regarding Inva lidity of US Patent No 10,335, 462, In re Ozempic Semaglutide Patent Litigation, No 1...

cite Cite Document
Analyze

1001 Exhibit: US10335462

Document IPR2023-00724, No. 1001 Exhibit - US10335462 (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1017 Exhibit: US5512549

Document IPR2023-00724, No. 1017 Exhibit - US5512549 (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1069 Exhibit: Remington 20th ed

Document IPR2023-00724, No. 1069 Exhibit - Remington 20th ed (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1049 Exhibit: ICH 1994

Document IPR2023-00724, No. 1049 Exhibit - ICH 1994 (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1082 Exhibit: Scheduling order

Document IPR2023-00724, No. 1082 Exhibit - Scheduling order (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1012 Exhibit: Lovshin 2009

Document IPR2023-00724, No. 1012 Exhibit - Lovshin 2009 (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze

1014 Exhibit: NCT773

Document IPR2023-00724, No. 1014 Exhibit - NCT773 (P.T.A.B. Mar. 16, 2023)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 43 44 45 46 47 ... >>